Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 210 participants.

Also called NCT04023344

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 210 participants (enrolled count) (from the registry)
Sponsor
  • Geropharm Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04023344
Other papers using this trial's data
  • Efficacy and safety of GP40021 insulin lispro biphasic compared with Humalog Mix 25 in Type 2 diabetes mellitus patients Journal of comparative effectiveness research, 2021-01 DOI, PubMed 33355484

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04023344. Randomized; no masking; primary purpose treatment. Start 2018-03-14 (actual); primary completion 2019-01-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients
Condition
Diabetes Mellitus, Type 2
Condition
Diabetes Mellitus
Intervention (Drug)
Humalog Mix25
Intervention (Drug)
Insulin Lispro Biphasic 25
Lead sponsor
Geropharm (class: industry)

Record details

Record id
cardio:ct-nct04023344
Content hash
10d9d800520e2b9b2157ee5d518266734002ef87d6d52a41b1b114fb97a8bd9b